Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02031250 · ClinicalTrials.gov registry record · Phase 2
Randomized Phase II Study of DCE-MRI-based Dose Escalation for Poor-prognosis and Neck Cancer
A Phase 2 study, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 106
- Enrollment target
NCT02031250 is a Phase 2 study that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 106 participants.
The verdict
NCT02031250, a Phase 2 study, has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 106 participants
- Enrollment target
Study Summary
This study aims to improve locoregional control of poor prognosis Head and Neck Cancer (HNC) patients by selectively escalating the radiotherapy dose to subvolumes of tumor likely to be resistant to standard Radiation Therapy (RT) using DCE-MRI (Dynamic Contrast Enhanced Magnetic Resonance Imaging). Standard doses of radiotherapy to the rest of the tissues and surrounding normal tissues will be maintained.
Interventions
- DRUG Carboplatin
- DRUG Cisplatin
- RADIATION IMRT (Intensity-Modulated Radiation Therapy)
- RADIATION Boost Radiation to Hypoperfused Volumes
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2014-02 |
| Est. Completion | 2023-02-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02031250
The ClinicalTrials.gov registry entry for NCT02031250 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Carboplatin is the first listed.
NCT02031250 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02031250 about?
NCT02031250 is a clinical study titled "Randomized Phase II Study of DCE-MRI-based Dose Escalation for Poor-prognosis and Neck Cancer". This study aims to improve locoregional control of poor prognosis Head and Neck Cancer (HNC) patients by selectively escalating the radiotherapy dose to subvolumes of tumor likely to be resistant to standard Radiation Therapy (RT) using DCE-MRI (Dynamic Contrast Enhanced Magnetic Resonance Imaging)....
What is the current status of trial NCT02031250?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 106 participants. The study started on 2014-02. Estimated completion is 2023-02-22.
What interventions are being tested in trial NCT02031250?
The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), IMRT (Intensity-Modulated Radiation Therapy) (RADIATION), Boost Radiation to Hypoperfused Volumes (RADIATION).
Who is sponsoring clinical trial NCT02031250?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.